DEF: Vor Biopharma Sets June 11, 2026 Annual Meeting

Vor Biopharma Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, with key proposals including director elections and equity plan amendments.

Summary

• Vor Biopharma Inc. is holding its 2026 Annual Meeting of Stockholders on June 11, 2026, at 9:00 a.m. Eastern Time, exclusively via a live webcast.
• The meeting agenda includes the election of two Class II directors for three-year terms, approval of an amendment and restatement of the 2021 Equity Incentive Plan, and ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• The company is providing proxy materials electronically via a Notice of Internet Availability of Proxy Materials, with paper copies available upon request.
• The record date for the meeting is April 15, 2026.
• The company has detailed its corporate governance practices, including board leadership structure and risk oversight.
• The proposed amendment to the 2021 Equity Incentive Plan aims to revise the 'Evergreen Provision' to include shares issuable upon exercise of pre-funded warrants in the annual share reserve increase calculation and to provide for accelerated vesting of time-based awards upon an employee's death.
• The filing also includes information on executive and director compensation, including details on stock option repricings in February and December 2025.
• Ernst & Young LLP has served as the company's independent auditor since 2020, with audit fees for 2025 totaling $956,250.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it outlines standard corporate governance procedures and plans for future equity incentives, but also notes past filing delays and stock option repricings.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• The proposed amendment to the equity incentive plan aims to attract and retain talent and align interests with stockholders.
• The board composition includes directors with significant experience in the biotechnology and venture capital industries.
• The company has a robust corporate governance framework, with a majority of independent directors.
• The Audit Committee has determined that Ernst & Young LLP meets independence requirements and has financial expertise.

Negatives

• The company experienced a delay in filing Section 16(a) reports for Qing Zuraw due to a delay in receiving EDGAR filing codes.
• Two stock option repricings occurred in February and December 2025, indicating that a significant number of options were underwater, suggesting prior grant prices may have been too high relative to market performance at those times.

Risks

• The company's reliance on equity compensation to attract and retain talent could lead to dilution for existing stockholders if not managed carefully.
• The amendment to the equity incentive plan, by including pre-funded warrants in the Evergreen Provision calculation, could potentially increase future dilution.
• The company's business transformation from treating hematological malignancies to autoimmune diseases carries inherent risks associated with clinical development and potential commercialization.

Future Outlook

The company is advancing its lead asset, telitacicept, through two Phase 3 global clinical trials for myasthenia gravis and Sjögren's disease, indicating a focus on late-stage development and potential commercialization.

Management Comments

• We believe that hosting a virtual meeting is in the best interest of our stockholders and enables increased stockholder attendance.
• We believe that providing an equity stake in the future success of our business encourages our employees to be highly motivated to achieve our long-term business goals and to increase stockholder value.
• We are committed to effectively monitoring our equity plan share reserve, both in terms of how large such reserve is (our overhang... ) and how quickly we use such share reserve (our burn rate...), to ensure that we maximize stockholders value by granting the appropriate number of equity incentive awards necessary to attract, reward, and retain employees.

Industry Context

StockSavvy.ai notes that Vor Biopharma's strategic shift towards autoimmune diseases and its reliance on equity compensation are common trends in the competitive biotechnology sector, where attracting specialized talent is crucial for advancing clinical pipelines.

Corporate Governance

Related Party Transactions

• Vor Biopharma entered into a securities purchase agreement in December 2024 with investors including those who became beneficial owners of over 5% of its Common Stock, issuing shares and warrants for approximately $55.6 million. Related parties Reprogrammed Interchange LLC and RA Capital Healthcare Fund, L.P. participated.
• In June 2025, the company issued pre-funded warrants for approximately $175.0 million to accredited investors, including RA Capital Healthcare Fund, L.P., Forbion Growth Opportunities Fund III Coperatief U.A., and entities affiliated with Venrock Healthcare Capital Partners.
• A license agreement was entered into with RemeGen Co., Ltd. in June 2025, along with a securities purchase agreement with a subsidiary of RemeGen, Yantai Rongpu Investment Partnership Limited, for warrants.
• In December 2025, the company sold approximately $150.0 million in shares to investors, including RA Capital Healthcare Fund, L.P. and ForGrowth III PA B.V.
• In March 2026, the company sold approximately $75.0 million in shares to investors, including TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P.
• Vor Biopharma sold intellectual property related to previous product candidates to SyzygyMed Inc. for $1.1 million in cash. SyzygyMed is wholly owned by Reprogrammed Interchange LLC, a significant stockholder.
• Directors Wouter Joustra, Andrew Levin, and Erez Kalir are affiliated with entities that are significant stockholders (ForGrowth III PA B.V., RA Capital Healthcare Fund, L.P., and Reprogrammed Interchange LLC, respectively).

Stakeholder Impact

• Shareholders will vote on key proposals affecting board composition and equity compensation, with potential implications for future dilution.
• Employees who are eligible for awards under the equity incentive plan may benefit from the proposed amendments, which aim to enhance retention and motivation.
• The company's strategic shift and ongoing clinical trials will impact all stakeholders by influencing the company's future direction and potential value.

Next Steps

• Stockholders to vote on director nominees, equity incentive plan amendment, and ratification of independent auditor.
• The company will file a Form 8-K with preliminary voting results within four business days after the Annual Meeting.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting. While it details important corporate governance and equity plan matters, it does not contain new financial results or strategic updates that would significantly alter the investment thesis. The company's business transformation and reliance on equity compensation are noted, but without new performance data, a 'hold' recommendation is appropriate pending further operational updates.

Keywords

Vor Biopharma, Proxy Statement, Annual Meeting, Director Election, Equity Incentive Plan, Ernst & Young LLP, Corporate Governance, Stockholder Meeting, Biotechnology